Current locoregional therapies and treatment strategies in hepatocellular carcinoma

被引：16

作者：

Cardarelli-Leite, L. ^{[1
]}

Hadjivassiliou, A. ^{[2
]}

Klass, D. ^{[2
]}

Chung, J. ^{[2
]}

Ho, S. G. F. ^{[2
]}

Lim, H. J. ^{[3
]}

Kim, P. T. W. ^{[4
]}

Mujoomdar, A. ^{[1
]}

Liu, D. M. ^{[2
]}

机构：

[1] Western Univ, Dept Med Imaging, London, ON, Canada

[2] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada

[3] BC Canc Vancouver Ctr, Dept Med Oncol, Vancouver, BC, Canada

[4] Univ British Columbia, Dept Surg, Vancouver, BC, Canada

来源：

CURRENT ONCOLOGY | 2020年 / 27卷

关键词：

Hepatocellular carcinoma; interventional radiology; transarterial radioembolization; chemoembolization; radiofrequency ablation; DRUG-ELUTING BEADS; PERCUTANEOUS ETHANOL INJECTION; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; RADIATION LOBECTOMY; LIVER-TRANSPLANTATION; DOUBLE-BLIND; CONVENTIONAL CHEMOEMBOLIZATION; SURGICAL RESECTION;

D O I：

10.3747/co.27.7171

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Locoregional therapies (LRTs) play an important role in the treatment of hepatocellular carcinoma (Hcc), with the aim of increasing overall survival while preserving liver function. Various forms of LRT are available, and choosing the best one depends on technical aspects, liver morphology, tumour biology, and the patient's symptoms. The purpose of the present review article is to provide an overview of the current evidence relating to the use of percutaneous ablation, transarterial chemoembolization, and transarterial radioembolization for the curative or palliative treatment of HCC. Special situations are also reviewed, including the combined use of systemic therapy and LRT, indications and techniques for bridging to transplant and downstaging, and the use of LRT to treat patients with Ficc and macrovascular invasion.

引用

页码：S144 / S151

页数：8

共 90 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process [J].

Adhoute, Xavier ;

Penaranda, Guillaume ;

Naude, Sebastien ;

Raoul, Jean Luc ;

Perrier, Herve ;

Bayle, Olivier ;

Monnet, Olivier ;

Beaurain, Patrick ;

Bazin, Christophe ;

Pol, Bernard ;

Le Folgoc, Gaelle ;

Castellani, Paul ;

Bronowicki, Jean Pierre ;

Bourliere, Marc .

JOURNAL OF HEPATOLOGY, 2015, 62 (04) :855-862

[3] Hepatocellular carcinoma: a review [J].

Balogh, Julius ;

Victor, David, III ;

Asham, Emad H. ;

Burroughs, Sherilyn Gordon ;

Boktour, Maha ;

Saharia, Ashish ;

Li, Xian ;

Ghobrial, R. Mark ;

Monsour, Howard P., Jr. .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 :41-53

[4] Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection [J].

Bertacco, Alessandra ;

Vitale, Alessandro ;

Mescoli, Claudia ;

Cillo, Umberto .

PERSONALIZED MEDICINE, 2020, 17 (02) :83-87

[5] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[6] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial [J].

Bruix, Jordi ;

Takayama, Tadatoshi ;

Mazzaferro, Vincenzo ;

Chau, Gar-Yang ;

Yang, Jiamei ;

Kudo, Masatoshi ;

Cai, Jianqiang ;

Poon, Ronnie T. ;

Han, Kwang-Hyub ;

Tak, Won Young ;

Lee, Han Chu ;

Song, Tianqiang ;

Roayaie, Sasan ;

Bolondi, Luigi ;

Lee, Kwan Sik ;

Makuuchi, Masatoshi ;

Souza, Fabricio ;

Le Berre, Marie-Aude ;

Meinhardt, Gerold ;

Llovet, Josep M. .

LANCET ONCOLOGY, 2015, 16 (13) :1344-1354

[7] Hepatocellular carcinoma: Consensus, controversies and future directions: A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting [J].

Burak, Kelly Warren ;

Sherman, Morris .

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 29 (04) :178-184

[8] Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design [J].

Burrel, Marta ;

Reig, Maria ;

Forner, Alejandro ;

Barrufet, Marta ;

Rodriguez de Lope, Carlos ;

Tremosini, Silvia ;

Ayuso, Carmen ;

Llovet, Josep M. ;

Isabel Real, Maria ;

Bruix, Jordi .

JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1330-1335

[9] Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus [J].

Cardarelli-Leite, Leandro ;

Chung, John ;

Klass, Darren ;

Marquez, Vladimir ;

Chou, Frank ;

Ho, Stephen ;

Walton, Henry ;

Lim, Howard ;

Tae Wan Kim, Peter ;

Hadjivassiliou, Anastasia ;

Liu, David M. .

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2020, 43 (03) :411-422

[10] Transcatheter Arterial Chemoembolization and Chemotherapy plus Sorafenib in a Large Hepatocellular Carcinoma with Arterioportal Shunt [J].

Chen, Jun ;

Chen, Shixi ;

Xi, Wei ;

Wu, Bei ;

Yu, Hui ;

Gao, Yang .

CASE REPORTS IN ONCOLOGICAL MEDICINE, 2014, 2014

← 1 2 3 4 5 6 7 8 9 →